CGRP antagonists work by blocking calcitonin gene-related peptide receptors, which are believed to play a role in neurogenic inflammation and neurovascular signaling associated with Visual Snow Syndrome. By inhibiting CGRP receptor activation, these compounds may potentially reduce neurological hyperexcitability and modulate aberrant sensory processing, potentially alleviating some visual and neurological symptoms of the syndrome.